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ABSTRACT 
 
Background: Autism spectrum disorders (ASD) are a group of complex developmental 
disabilities which can cause behavior, social, and communication deficits.  Anti-psychotic 
medications are often prescribed when symptoms such as aggression, irritability, hyperactivity, 
tantrums, and self-injurious behavior occur. 
Objective: To determine if anti-psychotic medications improve the behavior, social, and 
communication symptoms associated with ASD in children and adolescents. 
Search Strategy: Electronic literature searches were performed to find relevant studies and 
utilized the (1) Cochrane Database of Systematic Reviews, (2) Hispanic American Periodicals 
Index, (3) Medline, (4) PAIS International, (5) ProQuest Dissertations and Theses, (6) PsycInfo, 
(7) PubMed, (8) Springer LINK, (9) Taylor and Francis Journals, and (10) Sage Premier. 
Selection Criteria: Randomized controlled trials (RCTs) or quasi-experimental design (QED) 
studies of any dose of an anti-psychotic medication compared to a placebo or other prescription 
drug, in participants with autism spectrum disorder.  
Data Collection and Analysis: All studies which met the full-text level criteria were reviewed 
by a third party to validate the decision of inclusion. Meta-analyses in this review implemented 
both random and fixed-effects models. 
Main Results: Ten RCTs were included. Six studies evaluated a drug versus a placebo and four 
studies investigated the effects of two separate anti-psychotic medications or the efficacy of an 
additive medication to a drug and placebo group. 
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Author’s Conclusions: Limited evidence suggests the effectiveness of anti-psychotic 
medications in treating the behavior, social, and communication symptoms associated with 
autism; however, further research is needed to determine the implications of long-term use. 
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INTRODUCTION 
 
 Autism spectrum disorders (ASD) are a group of complex developmental disabilities that 
result in behavior, social, and communication deficits.  Recent data shows that 1 in 88 children 
have an ASD (CDC, 2012). However, the number of cases of autism appears to be rising. It is 
not yet clear whether this occurrence is due to improved detection methods and reporting of 
autism, an actual increase in the amount of cases, or a combination of both (Mayo Foundation for 
Medical Education and Research, 2010).  
 There are five different categories of ASDs; autistic disorder (also called “classic” 
autism), Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-
NOS), Rett syndrome and childhood disintegrative disorder. The American Psychiatric 
Association's Diagnostic and Statistical Manual-IV, Text Revision (DSM-IV-TR) 1 provides 
standardized criteria to assist in diagnosing ASD and is summarized as follows: 
• Autistic disorder: A person diagnosed with autistic disorder shows clinically significant 
impairments in social and communication behaviors, as well as restricted, repetitive, or 
stereotyped patterns of behavior. Beginning prior to 3 years of age, individuals with 
autistic disorder display deficits or abnormal functioning in a minimum of one of the 
following areas: (1) social interaction, (2) language as utilized in social communication, 
or (3) symbolic or imaginative play (American Psychiatric Association [APA], 2000).  
• Asperger syndrome: Individuals with Asperger syndrome generally exhibit milder 
symptoms of autistic disorder.  They may have social deficits and display repetitive 
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behaviors.  However, those with Asperger syndrome do not typically display severe 
language or cognitive deficits (APA, 2000). 
• Pervasive developmental disorder not otherwise specified: Those who do not meet all of 
the criteria for autistic disorder or Asperger syndrome due to atypical or sub-threshold 
symptomatology or late age of onset may be diagnosed with PDD-NOS. (APA, 2000). 
• Rett syndrome: This condition primarily affects girls. It was recently discovered that Rett 
syndrome is caused by mutations in the methl-CpG-binding protein 2 (MeCP2) gene 
(Amir & Zoghbi, 2000). Males born with this defective gene do not have a second X 
chromosome to compensate for the mutation (NINDS, 2011). Consequently, the defect 
often results in miscarriage, stillbirth, or premature death. Since females have two X 
chromosomes, the other X chromosome is normal enough for the child to survive. Those 
with Rett syndrome show typical perinatal and psychomotor development. However, at 5 
to 30 months of age individuals experience the loss of previously acquired purposeful 
hand skills and the onset of severely impaired expressive and receptive language 
development and clinically significant psychomotor regression (APA, 2000). 
• Childhood disintegrative disorder: A condition in which children develop normally 
before age 10, after which, children may lose language, motor, social, and other skills 
they previously acquired (APA, 2000).  
 There is currently no single gene or genetic test that definitively diagnoses autism (El-
Fishawy & State, 2010). The diagnosis of autism remains primarily based on clinical observation 
and assessment of neurological, cognitive, and language abilities. A first step often includes a 
questionnaire or other screening instrument to collect information about a child’s development 
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and behaviors (NINDS, 2012). Some screening instruments depend entirely on parent 
observations, while others utilize a combination of parent, physician, and other professional’s 
reports and observations. If the screening shows the possibility of an ASD, a more 
comprehensive evaluation is recommended including a complete neurological, cognitive, and 
language assessment (NINDS, 2012). 
 Social interaction issues are some of the most common deficits associated with ASD. 
These symptoms often include avoidance or hypersensitivity to eye and physical contact, the 
presence of neutral or inappropriate facial expressions, difficulty understanding the feelings of 
others, and not understanding or recognizing personal space boundaries (CDC, 2010). 
 Communication deficits are frequently seen in individuals with ASD and manifested in 
their difficulty in using or understanding gestures, and interpreting body language or tone of 
voice (CDC, 2010). Developmentally, these communication issues can also include delayed 
speech and language, repetition of words or phrases (echolalia), speaking in an unusual manner, 
and use of idiosyncratic grammar (CDC, 2010). 
 Behavior issues can include hyperactivity, impulsivity, aggression, self-injury, and short-
attention span. It is quite common for individuals with ASD to display hyper-organized 
behaviors such as lining up objects or exhibit unusual interests or behaviors that are viewed as 
obsessive interests or repetitive motions. Individuals with ASD may thrive on routine by 
following a strict set of rituals. Any change in these types of routines or rituals can lead to severe 
frustration or tantrums (CDC, 2010).  
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 There is currently no known cure for autism; however, the combination of behavioral 
therapy, specialized therapies, and medication are commonly used to manage the symptoms of 
ASD. Medications are frequently implemented when symptoms such as aggression, irritability, 
hyperactivity, tantrums and self-injurious behavior occur but are not used to treat the core 
symptoms of ASD. The classes of medications most frequently used to treat the behavioral 
problems associated with ASD include anti-depressants, stimulants, mood stabilizers, and anti-
psychotics. Of these classes, anti-psychotic medications are the most commonly prescribed 
medication for children with ASD (Cascade, Kalali & Feifel, 2008).   
 In 2006, the U.S. Food and Drug Administration approved risperidone, an anti-psychotic 
drug intended for use with adults, for the treatment of irritability in children and adolescents with 
autism. This general labeling of irritability also included treatment of behaviors such as 
aggression, self-injury, and tantrums. The effectiveness of risperidone in the treatment of 
irritability associated with pediatric ASD was examined in two 8-week, placebo-controlled trials 
monitoring 156 patients aged 5-16 years of age. The results of this study were evaluated and 
indicated that children treated with risperidone attained significantly improved scores for certain 
behavioral symptoms associated with autism compared to children being treated with a placebo.  
 Only one study has been identified that assessed the efficacy of anti-psychotic 
medications in treating the core features of ASD (Barnard, Young, Pearson, Geddes, & O’Brien, 
2002). The study conducted by Barnard and colleagues reviewed 19 trials conducted between 
1992 and 1999. Due to the limited number of studies, no restrictions were placed on the study 
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designs within this review. The majority of studies focused on children between the ages of 4 
and 18.  
 The studies contained a moderately homogenous group of patients who were severely 
affected by their behaviors that were predominantly aggressive to self-injurious. Two studies 
implemented a randomized, double blind crossover design with the remaining being prospective, 
retrospective, or non-randomized. Thirteen studies examined the effects of risperidone, three 
studies assessed olanzapine, and one study each investigated quetiapine, amisulpride, and 
clozapine.  
 Barnard et al (2002) reviewed the effects of these medications on social functioning, 
repetitive behaviors, language, aggression, hyperactivity, mood, and cognition. The studies 
analyzed were characterized by a lack of blinding or randomization, an absence of systematic 
and consistent measures among cases, and the use of small sample sizes, in addition to the use of 
other medications. Barnard et al (2002) explained that much of the available research was based 
upon case studies in which researchers may have been biased to only report those patients who 
responded. The information gathered from these 19 included studies led Barnard and colleagues 
to conclude that there was inadequate evidence to inform practice reliably and that well designed 
randomized trials were needed.  
 Since the report performed by Barnard and colleagues (2002) there have been no 
systematic reviews or meta-analyses that assess the efficacy of anti-psychotic medications in 
treating the common behavioral issues associated with ASD in children or adolescents.  Thus, the 
purpose of this study was to conduct a systematic review and meta-analysis to determine the 
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efficacy of anti-psychotic medications in treating the behavior, social, and communication 
deficits associated with ASD in children and adolescents and thereby add to the body of 
knowledge currently available on the topic. This study sought to advance the review performed 
by Barnard and colleagues by expanding the (1) number of databases accessed in the information 
retrieval process, (2) the chronological dates used in the information retrieval process, (3) the 
data analysis to include a quantification of the treatment effects using meta-analytic procedures, 
and (4) expanding beyond English language only databases.  
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METHOD 
 
Search Strategy 
 Electronic literature searches were performed to find relevant studies and utilized the (1) 
Cochrane Database of Systematic Reviews, (2) Hispanic American Periodicals Index, (3) 
Medline, (4) PAIS International, (5) ProQuest Dissertations and Theses, (6) PsycInfo, (7) 
PubMed, (8) Springer LINK, (9) Taylor and Francis Journals, and (10) Sage Premier. To locate 
pertinent studies the search terms were categorized and combined according to: 
Diagnostic: ‘autism’, ‘anti-psychotic’, ‘children’, ‘adolescents’ 
Symptom: ‘atypical’, ‘behavior’, ‘social’, ‘communication’, ‘speech’, ‘intervention’ 
Drug Treatment: ‘medication’, ‘trial’, ‘ risperidone’, ‘aripiprazole’, ‘haloperidol’, ‘olanzapine’, 
‘thioridazine, ‘quetiapine’, ‘ clozapine’ 
Study Design: ‘randomized controlled trial’, ‘quasi-experimental design trial’  
Inclusion Criteria 
 Decisions for studies to be included were made at two levels; (1) title and abstract 
retrieval, and (2) full-text retrieval. Studies included at the title and abstract retrieval level must 
have met the following criteria in order to advance to the full-text retrieval stage; (1) the use of 
anti-psychotic medications in treating behavioral outcomes, and (2) participants must have been 
under 18 years of age. Any title or abstract meeting these conditions advanced to the full text 
retrieval stage in which a complete manuscript of each study was obtained and evaluated for 
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inclusion criteria including; (1) the person receiving treatment must have been clinically 
diagnosed with autism, Asperger syndrome or PDD-NOS, (2) the treatment must have included 
anti-psychotic medications in treating the behavior, social, or communication issues of children 
and adolescents, (3) participants must have been between 2 and 18 years of age, (4) there must 
have been a minimum of three participants included within the clinical trial, and (5) the study 
must have used a randomized controlled trial or quasi-experimental research design. 
Study Coding 
 All studies which met the full-text level criteria were reviewed by a third party to validate 
the decision of inclusion. The coding of each included study was performed independently by 
two coders.  Once both coders completed the coding for a study, they compared the coding 
conclusions. If there were any differences in coding judgments, the differences were discussed to 
reach a consensus on the coding decision.  In the event they were unable to reach a consensus, a 
third coder evaluated the study and made a final decision. Every article included was coded to 
determine the reporting of the variables listed below. A codebook was created to provide 
definitions of each item on the coding form and is located in Appendix B.  
Participant Characteristics: The participants for this review must have had a primary clinical 
diagnosis of autism, Asperger syndrome, or PDD-NOS. Studies involving participants diagnosed 
with Rett syndrome or childhood disintegrative disorder were not included.  Participants must 
have been between the ages of 2 and 18 years.  
Treatment Characteristics: Only psychopharmaceutical interventions to treat the behavior, social, 
or communication deficits associated with ASD were used as the treatment agent. There were no 
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restrictions regarding the duration of clinical trial, frequency of medication administration, or 
dosage of medication(s).  
Outcomes Characteristics: The behavior outcomes of interest were those related to aggression, 
tantrums, self-injurious behaviors, repetitive tendencies, hyperactivity, and irritability. The social 
outcomes of interest were those related to social withdrawal and social responsiveness. The 
communication outcomes of interest were those associated with speech, language, and nonverbal 
communication. Studies that assessed the physiological outcomes of pharmaceutical intervention 
(e.g., metabolic changes, weight gain, prolactin levels, etc.) were not included. 
Design Characteristics:  Only randomized controlled trials and quasi-experimental design trials 
were included in this review. Studies utilizing a single subject, prospective or retrospective 
research design were excluded.   
Data Calculation 
 Since the outcome data of included studies was presented in varying formats, 
Comprehensive Meta-Analysis (CMA) (Borenstein, Hedges, Higgins & Rothstein, 2005) 
software was used to analyze the treatment effect sizes. This software is capable of accepting 
data in more than 100 different formats in order to convert it to a common effect size and 
variance.  
Effect Size Calculations 
 
 The appropriate formula, in CMA (Borenstein et al., 2005) was used to calculate a 
standardized mean difference with a small sample size correction (Hedges’ g). The calculation of 
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the treatment effect was based on the mean difference between the treated and comparison 
groups, accounting for the variance of measurement associated with participant performances.  
The basic formula is as follows: 
TXmean - CTLmean 
g =     ______________ 
  SDpooled groups 
 
 When means and standard deviations were not provided, treatment effects were 
calculated using the standard effect size formulae for F-Test, t-test, or p value. All reported 
values were based on a calculation of Hedges’ g and were interpreted according to standards 
provided by Cohen (1988): small effect = 0.0 to .20; medium effect = 0.20 to 0.70; large effect = 
0.70 or greater. 
Synthesis of Effect Sizes 
 
 Using the standardized mean difference (i.e., Hedges’ g), the effect sizes from each study 
were weighted by the inverse variance and averaged to create an overall study effect size. If a 
study reported more than one outcome for the same “treatment vs comparison group” 
comparison only a single effect size was included in the meta-analysis for any outcome measure. 
If a study involved more than two groups only the “treatment vs control group” comparison was 
used to create a single effect size for the study. 
Homogeneity Analysis 
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 A homogeneity analysis was applied to examine whether the differences in a set of effect 
sizes may be considered a result of sampling error and/or a result of other participant and study 
factors. Data synthesis for this study was conducted using both a random and fixed effects 
model.  
In order to allow for the widest application of the available data, a random effects model 
was used for all data interpretations and conclusions. In the random effects procedure, the meta-
analyses provides effect size estimates that vary across studies as a result of variations among the 
study population parameters such as age, severity of behavior, as well as errors associated with 
the sampling of participants within the study populations. Thus, the results from a random effects 
model provides for an accounting of these variations to allow for a generalization of findings to 
the population represented by the studies sampled for this review and analysis (Kline, 2004). 
Publication Bias 
 
 To assess potential publication bias, the trim and fill procedure was applied. The analysis 
is provided in the resulting funnel plot (Rothstein, Borenstein, and Sutton, 2005). 
Sensitivity Analysis 
 
 The one study removed analysis examined the impact of a single study effect size on the 
overall effect size for any outcome with multiple studies measuring the same outcome. The 
procedures involved the removal of the effect size for a single study, recalculation of the average 
overall effect for the remaining studies, then removal of the next study effect size while replacing 
the previous study effect size to calculate the overall treatment effect. This method allowed for a 
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more precise picture of the contribution of each study to the overall treatment effect results, such 
that, those studies with larger sample sizes were given proportionately more weight than studies 
with small samples sizes when estimating the average effect size in any calculation. 
Moderator Analyses  
 
 Moderator analyses were performed to assess differences in the average effect sizes for 
the following study-level characteristics; (1) socioeconomic status, (2) sample source, (3) 
participant severity, and (4) participant ethnicity/race. The moderator analyses were conducted 
using the fixed effects model.      
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RESULTS 
Search Results 
 
 
    
  
 
 
 
 
 
 The initial search identified 340 studies. Of these, 314 were excluded as not relevant 
based on titles or abstracts. The remaining 26 studies were evaluated after retrieval of the full 
text. Upon review of the 26 studies, 16 studies were excluded for the following reasons. One 
study; Shea et al. (2004), was excluded in the analysis stage due to the author’s inclusion of 
participants diagnosed with childhood disintegrative disorder. A total of five studies were 
excluded due to a monotherapy design (Nicholson, Awad, & Sloman, 1998; Findling, Maxwell, 
& Wiznitzer, 1997; McDougle et al., 1997; Perry et al., 1997; Martin et al., 1999).  Four studies 
were excluded due to utilization of a discontinuation/continuation maintenance study design 
(Gencer et al., 2007; McCracken et al., 2005; Troost et al., 2005; Marcus et al., 2011). Five 
Initial Search: 340 references 
Full Text Retrieval: 26 references 
Excluded: 16 references 
Monotherapy Design (n=5) 
Maintenance Design (n=4) 
Prospective design (n=5) 
Retrospective design (n=1) 
Participant diagnosed with CDD 
(n=1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Excluded: 314 references 
Not relevant from title/abstract 
(n=314) 
Study Inclusion: 10 references 
Figure 1: Flowchart of search results 
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studies were excluded due to the utilization of a prospective case series study design (Fisman & 
Steele, 1996; Hardan, Johnson, & Hrecznyj, 1996; Malek-Ahmadi & Simonds, 1998; Horrigan, 
Barnhill, & Courvoise, 1997; Zuddas et al., 1996). Lastly, a study by Posey et al. (1999) was 
excluded due to a retrospective case series study design. Ten studies met the inclusion criteria to 
be analyzed in this review. Table 1 shows the characteristics of participants within these studies. 
While this review allowed for both RCT and QED study designs the ten studies which met 
inclusion criteria all utilized a RCT design. 
         Table 1: Characteristics of participants 
Study    
Name  
Tx  
n 
Tx 
Mean 
Age 
(yrs) 
Tx 
% 
Male 
Tx 
Mean 
Weight 
(kg) 
Com 
n 
Com 
Mean 
Age 
(yrs) 
Com 
% 
Male 
Com 
Mean 
Weight 
(kg) 
Dollfus 5 6.9 56% NR 4 6.9 56% NR 
McCracken 49 8.8 80% NR 52 8.8 83% NR 
Nagaraj 19 4.8 84% 16.2 20 5.3 90% 18.3 
Pandina 20 7.4 70% 30.4 21 7.1 86% 27.3 
Luby 11 4.1 81% 19.2 11 4 66% 18.1 
Miral 13 10 73% 33.3 15 10.9 87% 42.1 
Akhondzadeh 20 7.5 78% 26.2 20 7.1 75% 26 
Owen 46 9.7 89% 43.9 49 8.8 86% 40.6 
Marcus 47 9.5 89% 43.1 38 10.2 92% 42.2 
Rezaei 20 8.2 65% 26.8 20 7.9 70% 27.4 
           
Overall Treatment Effect 
 An analysis of the general effects of anti-psychotic drug treatment was assessed by first 
calculating an effect size for all outcomes in all 10 included studies to produce a single study 
effect size.  Next these effect sizes were averaged for each study to produce a meta-analysis of an 
estimate of the overall treatment impact. Figure 2 displays the average effect of anti-psychotic 
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medications versus a comparison drug or placebo for all outcomes reported (g = 0.67, p = 0.000, 
95% CI = 0.49 to 0.86). This analysis suggested that anti-psychotic medications appear to have a 
statistically significantly positive effect on children and adolescents diagnosed with ASD to 
improve the behavior, social, and communication outcomes. 
 A test of heterogeneity was calculated using a fixed effects model to evaluate the amount 
of variation in study effect sizes beyond sampling error. The analysis resulted in a non-
significant measurement of heterogeneity (Q = 6.516, df = 9, p = 0.719), suggesting that 
variation in the effect sizes, and thus the treatment effect, can be attributed to factors other than 
sampling error, namely the drug intervention. To further substantiate this finding the overall 
analysis was subjected to a random effects model with the resulting g value, lower and upper 
limits, and p value being identical to the fixed effects result.  These findings support the 
assumption that, in general, the observed effect sizes were drawn from a similar population and 
generalizations are appropriate to all participants reported in the included studies and potentially 
to similar studies not included in this review. 
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Q= 6.516,  df= 9, p=.719
-2.0         0.0          2.0
Favors Placebo  Favors Drug
Study  Name Year Comparison Outcome Hedges’
g
Lower
Limit
Upper 
Limit
p-Value Exp 
n
Comp 
n
Dollfus 1992 Amisul v Bromo Combined 0.925 -0.346 2.215 0.160 5 4
McCracken 2002 Risp v Placebo Combined 0.576 0.180 0.972 0.004 49 52
Nagaraj 2005 Risp v Placebo Combined 0.889 0.242 1.536 0.007 19 20
Pandina 2006 Risp v Placebo Combined 0.637 -0.178 1.453 0.126 20 21
Luby 2006 Risp v Placebo Combined 0.302 -0.507 1.111 0.465 11 11
Miral 2007 Risp v Halp Combined 0.549 -0.191 1.288 0.146 13 15
Akhondzadeh 2009 Combined Combined 1.347 0.281 2.022 0.000 20 20
Owen 2009 Aripip v 
Placebo
Combined 0.692 0.220 1.103 0.001 46 49
Marcus 2009 Aripip v 
Placebo
Combined 0.656 0.217 1.092 0.003 47 38
Rezaei 2010 Risp+Topira v 
Risp+Placebo
Combined 0.421 -0.197 1.039 0.182 20 20
0.674 0.493 0.856 0.000
Hedges’ g & 95% CI
Figure 2: Overall treatment effect 
Publication Bias Analysis 
Publication bias addresses the possibility that the included studies, which are composed 
of peer-reviewed publications, may result in an inaccurate measurement of the drug treatment 
effect. To analyze potential publication bias a funnel plot of standard error by Hedges’ g was 
created. Figure 3 shows that the ten studies conform to the shape of the funnel plot suggesting 
one can be confident that the included studies constitute a representative sample of studies that 
may have not been identified and included in this review. Furthermore, the trim and fill analysis 
was then applied to the data, which trims exceptionally large studies and imputes small studies 
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that are purportedly missing. Under the fixed effect model the point estimate and 95% 
confidence interval for the combined studies was 0.67 (95% CI = 0.49 to 0.86). Using the trim 
and fill analysis these values remained unchanged. This symmetry suggests the absence of 
publication bias.  
A second publication bias analysis was also conducted by calculating the number of 
studies that would have to exist and not be included in this review to significantly alter the 
obtained treatment effect.  This analysis revealed that a total of 123 studies with an average 
treatment effect size of 0.0 would have to exist in order negate the current overall effect size of 
0.67. That is, while it is possible that one or more studies may not have been identified that 
would have met the inclusion criteria; these data suggest that it is reasonably unlikely additional 
studies, if identified, would statistically alter the observed treatment effect in this review. 
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Figure 3: Funnel plot of standard error by Hedges' g 
 
Overall Treatment Effect: Drug versus Placebo 
 An analysis was performed to evaluate the overall effect size of anti-psychotic 
medication treatment versus placebo treatment. Four studies were identified that examined the 
efficacy of risperidone compared to a placebo treatment (McCracken et al., 2002; Nagaraj, 
Singhi, & Malhi, 2005; Pandina et al., 2006; Luby et al., 2006) while two studies were identified 
that investigated the efficacy of aripiprazole versus placebo treatment (Owen et al., 2009; 
Marcus et al., 2009). All dependent variables were categorized into three major types of 
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outcomes: behavior, social, and communication. The following is a summary of the treatment 
effects for each outcome category.  
Overall Effect for Behavior Outcomes 
 
Several behavior outcomes are represented in the summary data below (e.g., 
hyperactivity, irritability, stereotypic behavior, etc.).  Table 2 provides a summary of both 
treatment medications. Risperidone exhibited an overall effect of g = 0.67 (p = 0.000, 95% CI= 
0.38 to 0.96) and Aripiprazole an overall effect of g = 0.65 (p = 0.000, 95% CI = 0.35 to 0.95). A 
meta-analysis of all behavior outcomes across both drugs and all studies, resulted in a 
statistically significant treatment effect of g = 0.66 (p = 0.000, 95% CI = 0.45 to 0.87) in favor of 
the treated participants for both drug types. 
Table 2: Overall effect for behavior outcomes 
Study 
Name Year Drug 
Hedges' 
g 
Lower 
Limit 
Upper 
Limit p-value Tx n Ctl n 
Luby  Risperidone 0.288 -0.520 1.097 0.484 11 11 
McCracken 2002 Risperidone 0.670 0.272 1.068 0.001 49 52 
Nagaraj 2005 Risperidone 0.918 0.269 1.567 0.006 19 20 
Pandina 2006 Risperidone 0.655 -0.206 1.516 0.136 18 20 
Fixed Effects Risperidone 0.669 0.375 0.963 0.000   
Marcus 2009 Aripiprazole 0.599 0.165 1.034 0.007 47 38 
Owen 2009 Aripiprazole 0.692 0.281 1.103 0.001 46 49 
Fixed Effects Aripiprazole 0.648 0.350 0.947 0.000   
 
Overall Effect for Social Outcomes 
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 The assessment of social outcomes (e.g., social withdrawal, social responsiveness, etc…) 
was conducted in three studies, all using the anti-psychotic medication risperidone (McCracken 
et al., 2002; Nagaraj et al., 2005;  Pandina et al., 2006).  A meta-analytic analysis revealed a 
statistically significant improvement for the treated participants of g = 0.55 (p = 0.000, 95% CI = 
0.26 to 0.83). Table 3 presents a summary of the effects associated with each study and an 
overall aggregate of the treatment effect. 
Table 3: Overall effect for social outcomes 
Study 
Name Year Drug 
Hedges' 
g 
Lower 
Limit 
Upper 
Limit 
p-
Value Tx n Ctl n 
McCracken 2002 Risperidone 0.435 0.043 0.827 0.030 49 52 
Nagaraj 2005 Risperidone 0.810 0.169 1.450 0.013 19 20 
Pandina 2006 Risperidone 0.566 0.032 1.101 0.038 27 28 
   0.545 0.262 0.829 0.000   
Overall Effect for Communication Outcomes 
The assessment of the treatment effects on communication outcomes (e.g., inappropriate 
speech) was also performed in the same three studies as the social outcomes (McCracken et al., 
2002; Nagaraj et al., 2005; Pandina et al., 2006) and yielded a statistically significant treatment 
effect of g = 0.55 (p = 0.000, 95% CI = 0.26 to 0.83).  Table 4 presents a summary of the effects 
associated with each study and the meta-analysis of the combined studies for the measurement of 
social outcome effects. 
 
 
 
 
 
21 
 
Table 4: Overall effect for communication outcomes 
Study 
Name Year Drug 
Hedges' 
g 
Lower 
Limit 
Upper 
Limit 
p-
Value Tx n Ctl n 
McCracken 2002 Risperidone 0.435 0.043 0.827 0.030 49 52 
Nagaraj 2005 Risperidone 0.880 0.235 1.525 0.008 19 20 
Pandina 2006 Risperidone 0.520 -0.015 1.055 0.057 26 28 
   0.545 0.261 0.829 0.000   
Summary of Treatment Effects 
 
 Overall, risperidone had a statistically significant effect across studies on behavior (g = 
0.66), social (g= 0.55), and communication (g = 0.55) outcome measures, suggesting improved 
scores for these outcomes were due to the daily treatment intervention of risperidone. 
Risperidone vs Placebo Effect as Moderated by SES 
 
 In order to assess the potential impact of specified independent variables on the 
magnitude of the treatment effect, a moderator analysis was conducted for the variables of 
socioeconomic status (SES), sample source, participant severity, and race/ethnicity. These 
analyses were conducted under the fixed effects model with a non-significant Q value resulting 
(p= 0.05). Table 5 illustrates the impact of SES on the effect of risperidone when compared to a 
placebo.  Two studies; McCracken et al. (2002) and Nagaraj et al. (2005), reported participants 
from an SES group composed of Middle-Upper class participants. One study (Pandina et al., 
2006), provided no information regarding the SES of participants and another single study (Luby 
et al., 2006), had an unclear definition of SES for group participants.                                                                          
 Due to the limited number of studies reporting socioeconomic status, it was not possible 
to draw a reliable conclusion on the impact this factor had in the measured treatment effect of 
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risperidone versus placebo. The treatment effect could suggest a potential finding in which 
studies reporting less information on SES might exhibit smaller treatment effects. 
Table 5: Risperidone versus placebo effect as moderated by SES 
Moderator 
Study 
Name Year Hedges's g 
Lower 
Limit 
Upper 
Limit p-Value Tx n Ctl n 
Mid-Up McCracken 2002 0.576 0.180 0.972 0.004 49 52 
Mid-Up Nagaraj 2005 0.889 0.242 1.536 0.007 19 20 
Mid-Up     0.661 0.324 0.999 0     
NR Pandina 2006 0.637 -0.178 1.453 0.126 20 21 
Unclear Luby 2006 0.302 -0.507 1.111 0.465 11 11 
Overall     0.612 0.321 0.903 0     
Risperidone versus Placebo Effect as Moderated by Sample Source 
 
 The assessment of the moderator effect of the source from which the study sample was 
drawn is presented in Table 6. Two studies reported no information as to the sample source 
(Pandina et al., 2006 & McCracken et al., 2002) while one study indicated that the participants 
were drawn from a clinic (Nagaraj et al., 2005) and another study where participants were drawn 
from several different sources (Luby et al., 2006). Due to the small number of studies that 
reported the source of their samples, an analysis of the overall effect of the sample was not 
warranted or appropriate. 
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Table 6: Risperidone versus placebo effect as moderated by sample source 
Moderator 
Study 
Name Year Hedges's g 
Lower 
Limit 
Upper 
Limit p-Value Tx n Ctl n 
Clinic Nagaraj 2005 0.889 0.242 1.536 0.007 19 20 
Mixed Luby 2006 0.302 -0.507 1.111 0.465 11 11 
NR McCracken 2002 0.576 0.180 0.972 0.004 49 52 
NR Pandina 2006 0.637 -0.178 1.453 0.126 20 21 
NR     0.588 0.232 0.944 0.001     
Overall     0.612 0.321 0.903 0     
Risperidone versus Placebo Effect as Moderated by Participant Severity 
 
 A summary of the moderating effect of the participant severity reporting is presented in 
Table 7. Since only a single study was represented for each of four different reporting levels of 
participant severity, these data can only be understood as descriptive of the individual study. The 
absence of multiple studies reporting information relative to participant severity when comparing 
risperidone versus placebo treatment provided no useful information as to the potential impact of 
participant severity on the magnitude of the treatment effect for any single severity rating. 
Table 7: Risperidone versus placebo effect as moderated by participant severity 
Moderator 
Study 
Name Year Hedges's g 
Lower 
Limit 
Upper 
Limit p-Value Tx n Ctl n 
Mix Luby 2006 0.302 -0.507 1.111 0.465 11 11 
Mod-Sev McCracken 2002 0.576 0.180 0.972 0.004 49 52 
NR Nagaraj 2005 0.889 0.242 1.536 0.007 19 20 
Sev Pandina 2006 0.637 -0.178 1.453 0.126 20 21 
Overall     0.612 0.321 0.903 0     
Risperidone versus Placebo Effect as Moderated by Participant Ethnicity/Race 
 
 Table 8 displays the effect of participant ethnicity/race in the efficacy of risperidone 
versus placebo treatment. Three studies; Luby et al. (2006), McCracken et al. (2002), and 
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Pandina et al. (2006), reported a mixed sample of participant ethnicity/race. The aggregated 
effect across the studies was g = 0.61 (p = 0.000, 95% CI = 0.32 to 0.90). One study (Nagaraj et 
al., 2005) did not report participant ethnicity/race and showed an effect size almost twice as large 
as the other three studies reporting a mixed ethnic/racial representation. While the data are 
sparse, the results do call into question the credibility of the effect size of the study not reporting 
information regarding participant ethnicity/race given that the resulting effect is almost twice as 
large as the other three studies combined. 
Table 8: Risperidone versus placebo effect as moderated by participant ethnicity/race 
Moderator 
Study 
Name Year Hedges’ g 
Lower 
Limit 
Upper 
Limit p-Value Tx n Ctl n 
Mixed Luby 2006 0.302 -0.507 1.111 0.465 11 11 
Mixed McCracken 2002 0.576 0.180 0.972 0.004 49 52 
Mixed Pandina 2006 0.637 -0.178 1.453 0.126 20 21 
Mixed     0.541 0.216 0.867 0.001     
NR Nagaraj 2005 0.889 0.242 1.536 0.007 19 20 
Overall     0.612 0.321 0.903 0     
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CONCLUSION 
 
 The purpose of this systematic review and meta-analysis was to evaluate the efficacy of 
anti-psychotic medications in treating the maladaptive behaviors associated with ASD in 
children and adolescents. Electronic literature searches were performed to find relevant studies. 
Ten clinical trials were found that met the inclusion criteria for this review. The meta-analysis in 
this review implemented both random and fixed-effects models.  
 Six of the included studies investigated the effects of a drug versus a placebo and four 
studies examined the effects of two separate anti-psychotic medications or the efficacy of an 
additive medication to a drug and placebo group. Based on this selection of studies, an analysis 
was performed to assess the causal effect of the drug treatments and the potential moderating 
effect of selected independent variables. The following provides a discussion of the results and 
conclusions to be drawn. 
Overall Treatment Effect 
 Overall, anti-psychotic medications were shown to have a positive and statistically 
significant effect on the behavior, social, and communication outcomes reported for children and 
adolescents with ASD. The systematic review performed by Barnard and colleagues (1992) was 
unable to inform reliably on the use of anti-psychotics due to the lack of RCTs available at the 
time. However, based on this analysis, the overall effect size suggested that daily use of an anti-
psychotic medication for at least eight weeks improved the behavior, social, and communication 
deficits associated with ASD.  
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 The aggregation of effect sizes across multiple studies using different medications, 
varying treatment characteristics, and study design characteristics did not provide a clear 
interpretation of the effects of any particular medication or treatment protocol.  A more precise 
interpretation can only be made when the studies that are combined are similar across one or 
more important study features. 
Risperidone Treatment Effect 
Specifically, the results of the studies comparing risperidone to a placebo allowed for a 
causal statement of the treatment effect and indicated that risperidone produced a positive and 
statistically significant effect on behavior (g = 0.66), social (g = 0.55), and communication (g = 
0.55) symptoms. These results suggest that, when treated daily with risperidone, children and 
adolescents with ASD displayed an overall improvement on the measured treatment outcomes 
(e.g., aggressiveness, social withdrawal, speech, and self-injury).  
Overall Effect for Behavior Outcomes 
 
 An analysis of the overall effect for behavior outcomes also provided for a causal 
statement of the overall treatment effect. When treated with risperidone compared to a placebo, 
participants exhibited a positive and statistically significant effect on the behavior measures 
utilized across studies (g = 0.66). This result suggests that, when treated daily with risperidone, 
children and adolescents with ASD displayed an overall improvement on the measured behavior 
outcomes (e.g., irritability, hyperactivity/noncompliance, etc.). 
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Overall Effect for Social Outcomes 
 
 In relation to social outcomes, the data revealed that when treated with risperidone 
compared to a placebo, participants demonstrated a statistically significant positive but moderate 
effect on the social measures observed across studies (g = 0.55). This finding suggests that social 
behaviors (e.g., social withdrawal, lethargy, social responsiveness, etc.) improved when children 
and adolescents with ASD receive treatment daily with risperidone. 
Overall Effect for Communication 
 
 The analysis of the overall effect for communication outcomes allows for a causal 
statement of the overall treatment effect. When treated with risperidone compared to a placebo, 
risperidone produced a statistically significant positive moderate effect on the communication 
outcomes (g = 0.55). This result suggests that, when treated daily with risperidone, children and 
adolescents with ASD displayed an overall improvement on the reported communication 
outcomes (such as language skill and inappropriate speech). 
Aripiprazole Treatment Effect 
 Two studies were identified and included in this review that investigated the efficacy of 
aripiprazole in children and adolescents using a treatment vs placebo design (Owen et al., 2009 
& Marcus et al., 2009).  A meta-analysis was conducted and revealed an uneven reporting of 
outcome performances that would allow for a substantial causal conclusion. 
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 Overall Effect for Behavior Outcomes 
 The meta-analytic analysis for two studies examining the efficacy of aripiprazole in 
children and adolescents (Owen et al., 2009 & Marcus et al., 2009) also allow for a causal 
statement of the impact of the drug treatment with an overall treatment effect size of  g = 0.65. 
Due to the small number of studies available comparing aripiprazole to a placebo condition, the 
available data must be interpreted cautiously and is best understood as a descriptive estimate of 
the treatment effect of the individual studies. 
Overall Effect for Social Outcomes 
 
 The two studies (Owen et al., 2009 & Marcus et al., 2009) assessing the efficacy of 
aripiprazole in treating children and adolescents did not report social outcome measures.  
Therefore, an analysis of data could not be performed. 
Overall Effect for Communication Outcomes 
 
 Owen et al., (2009) and Marcus et al. (2009) examined the efficacy of aripiprazole in 
treating children and adolescents but did not report communication outcome measures. 
Consequently, an interpretation of data could not be made.  
Overall Effect of Moderator Variables 
 
  An analysis of the overall effect of moderator variables (i.e., SES, sample source, 
participant severity, and participant race) illustrated that too few studies reported details such as 
SES or participant race. As a result, an interpretation of the impact of these factors in a 
risperidone versus placebo comparison could not be made. 
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Limitations 
 There are several limitations to this study. 
1.  Only two studies observed the effects of anti-psychotic treatment for more than twelve weeks, 
so while a majority of participants had a positive response to treatment, results of this study only 
assess the short-term efficacy of anti-psychotic medications.  
2. This review focuses on the behavior, social, and communication improvement of children and 
adolescents with ASD and does not thoroughly examine the physiological implications of anti-
psychotic medication treatment.  
3. This analysis excluded studies with a participant diagnosis of childhood disintegrative disorder 
and Rett syndrome.  
4. There were too few studies represented for any treatment medication other than risperidone to 
support widespread application for use on children and adolescents with autism. 
5.  The reporting of potentially moderating variables was limited or absent in many studies 
making any explanatory interpretation of the nature of the treatment impact limited. 
Implications for Future Research 
 There is a need to enhance the research base through the use of RCT designed studies that 
analyze the effects of individual anti-psychotic medications on behavior, social, and 
communication skills through longer term trials and larger sample sizes. While it is apparent at 
least two anti-psychotic medications have a generally positive impact on maladaptive behaviors, 
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there is a lack of research investigating either the moderating variables that might contribute to 
an explanation as to the critical variables impacting the treatment effect or the long-term 
implications of routine anti-psychotic treatment. Do side effects of anti-psychotics subside over 
time? Or, does long-term use worsen the potential side effects? Also, does long-term use lead to 
drug tolerance and a need to increase daily dose over time? 
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APPENDIX A: CODING SHEET 
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                    Coding 
Number______ 
APA Citation:______ 
Publication Source: 
1. Journal Article 
2. Conference Paper 
3. Master Thesis 
4. Organization Report 
5. Technical Report 
6. Doctoral Dissertation 
7. Book or Book Chapter 
8. Not Reported 
9. Other________________________________ 
 
Funding Source (pg. ____ ): 
Subject Characteristics (pg. ____ ): 
 
 Groups Pre- 
treatment 
(n) 
Post- 
Treatment 
(n) 
Attrition 
(n) 
Follow-
up 
(n) 
Age 
(years) 
% male 
 T 
(1) 
       
 T 
(2) 
       
 C 
(1) 
       
 C 
(2) 
       
Com 
(1) 
       
Com 
(2) 
       
 
 
Comments: ________________________________________________________________ 
SES (pg.____ ) 
1. Low        5.   Middle-Upper 
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2. Middle        6.   Labeled Mixed 
3. Upper                                        7.   Unclear 
4.   Low-Middle       8.   Other__________  
            9.   Not Reported 
 
Sample Source: (pg.____ ) 
 1.   Public School       4.   Not Reported 
2.   Private School       5.   Unclear 
3.   Univ. Clinic / Outpatient Clinic      6.   Other__________ 
 
 Comments:_________________________________________________ 
 
Setting (pg.____  ) 
 1.   Urban        6.   Suburban-Rural 
2.   Suburban        7.   Unclear 
3.   Rural                   8.   Other__________ 
 4.   Urban-Suburban        9.   Not Reported 
 5.   Urban-Rural 
  
 Comments:_________________________________________________ 
 Geographic Setting: __________________________________________ 
 
Author’s Labeling of Participants: 
1.   Autism  2.   Asperger  3.   PDD-NOS  4.   Unclear                    
            5.   Not Reported 6.   Other______________________ 
 
Severity of Participants Pre-test (pg. ____  ) 
1. Mild                         5.   Severe 
2. Mild-Moderate                    6.   Unclear 
3. Moderate                        7.   Mixed 
4. Moderate-Severe                      8.   Not Reported 
 
Comments: __________________________________________________ 
Education Level of Participants (pg. ____ ): 
 1.   Pre-School                      6.   Clinic Only 
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 2.   K-5                                 7.   Unclear 
 3.   Middle School (6-8)                      8.   Other__________ 
 4.   High School (9-12)                    9.   Not Reported 
 5.   Homeschool 
 
Race/Ethnicity (pg. ____ ): 
1. African American           5.   White/Caucasian 
2. American Indian                       6.   Unclear 
3. Asian        7.   Mixed_______ 
4. Hispanic /Latino                       8.   Not Reported 
 
Intervention Characteristics: (pg. ____ ):  
 1.   Drug Name: ________________________      
 2.   Dose: ________________________ 
 3.   Length of intervention (pg. ____ ): ____________________________ 
 4.   Frequency of treatments: __________________________ 
 5.   Treatment setting: ____________________________ 
            6.   Side effects: _____________________________ 
 
Outcome Measure(s): (pg. ____  ) 
 
1. Norm Referenced Test (pg. ____ ) 
  _______________________________________________________________ 
 
Who administered the measure? (pg. ____ ) 
1. Physician/Researcher          4.   Unclear 
2. Parents                    5.   Not Reported 
3. Teacher Counselor/Clinician                    6.   
Other_____________________ 
 
2. Criterion Referenced Test (pg. ____ ) 
_______________________________________________________________ 
Who administered the measure? (pg. ____ ) 
1. Physician/Research                       4.   Unclear 
2. Parents                     5.   Not Reported 
3. Teacher Counselor/Clinician            6.   
Other_____________________ 
           
   3.   Rating Scale (pg. ____ ) 
_______________________________________________________________ 
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Who administered the measure? (pg. ____ ) 
1. Physician/Researcher            4.   Unclear 
2. Parents                        5.   Not Reported 
3. Teacher Counselor/Clinician          6.   
Other_____________________ 
 
 
Outcome Variables:  (pg. ____ ) 
Design Characteristic: (pg. ____ ) 
Recruitment Pool (pg. ____ ) 
1. Referral               4.   Unclear 
2. Criterion___________               5.   Not Reported 
3. Scores on Norm Referenced Test __________                          6.   Other_________ 
4. Existing Group 
5. Volunteer 
6. Waiting List 
 
Design Type (pg. ____ ) 
1. RCT 
2. Quasi-Experimental 
 
Subject Assignment (pg. ____ ) 
1. Individual Random    6.  Non-Matched Non-Random 
2. Whole Group Random    7.  Unclear 
            3.   Individual Matched-Random   8.  Not Reported 
4.   Matched Non-Random                                          9.  Other_____________________ 
 
Method of Random Assignment (pg. ____ ) 
1. Random Number Generation                             4.   Not Reported 
2. Simple Random         5. Allocation/Assignment 
3.   Coin Flip                         6. Other__________ 
4. Unclear             
 
Type of Analysis (pg. ____ ) 
            1.   Intent to Treat 
            2.   Treat Only 
 
 
 
36 
 
Individual Blinding 1 (pg. ____ )                  Group Blinding 2 (pg. ____ ) 
1. Researcher (pg. ____ )                                                      1.   Open 
2. Participants (pg. ____ )                                                     2.   Single Blind 
3. Intervener (pg. ____ )                                                        3.   Double Blind 
4. Assessor (pg. ____ )                                                          4.   Triple Blind 
5. No Blinding 
6. Unclear 
7.   Not Reported 
 
 
 
Two Groups 
Compared 
Group 1:                              Group 2: 
 
 
             Outcomes 
   
                 Groups     Exp      Ctl    Exp    Ctl    Exp     Ctl 
                    Mean       
                        SD       
         N at Posttest       
  N at Follow-up 1       
  N at Follow-up 2       
  N at Follow-up 3       
                 d-index    
                 F value    
                  t value    
                 p value    
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Publication Source 
Journal article - An article published in a periodical devoted to a particular subject matter; can be 
peer or non-peer reviewed.  
Conference paper - An original paper submitted and/or presented at a formal conference. 
Master thesis - A paper on a specific subject of original research by a candidate for a diploma or 
degree.  
Organization report - A paper describing results of a study that was performed for a government 
agency, private foundation, or corporate group. 
Technical report - A paper that explains the progress or results of technical or scientific research; 
usually not peer reviewed. 
Doctoral dissertation - A paper on a specific subject of original research by a candidate for a 
degree or professional qualification.  
Book or book chapter - A printed work of nonfiction. 
Not Reported - The format of publication was not reported. 
Other - A paper or article of any format other than those presented here. 
Subject Characteristics 
Control - A group of subjects used for comparison in a scientific experiment. 
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Experimental - A group of subjects used in an experiment to perform a test and an independent 
variable is applied (e.g., treatment).  
Attrition - A reduction in participants assigned to either experimental or control conditions. 
SES (socioeconomic status)  
An individual's or group's position within a hierarchical social structure. The author’s/authors’ 
designation of one of the following: 
Low 
Low-middle: includes reference to both low and middle levels of SES 
Middle 
Middle-upper: includes reference to both middle and upper levels of SES 
Upper 
Labeled mixed: includes reference to all levels of SES or a non-specific reference to a multi-
level SES representation (e.g., “…. participants represented all levels of SES). 
Unclear: A statement that does not explicitly indicate the SES of participants obtained.  
Other: A SES other than those presented here. 
Not reported: The SES of participants was not reported. 
 
 
Sample Source 
The organization from which participants were obtained before group assignment. 
School - A public or private institution in which instruction is given. 
Clinic - A facility; often affiliated with a hospital, university, or a private practice, that is 
committed to the diagnosis and treatment of outpatients. 
Not reported - The origin of the sample source was not reported. 
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Unclear - A statement that does not explicitly indicate a specific organization from which 
participants were obtained.  
Other – The sample of participants was obtained from a source other than those presented here 
Sample Setting  
The geographic location in which participants within a sample were retrieved. The 
author’s/authors’ designation of one of the following: 
Urban 
Suburban 
Rural 
Urban-Suburban: reference must include both and only these terms 
Urban-Rural: reference must include both and only these terms 
Suburban-Rural: reference must include both and only these terms 
Unclear: A statement that does not explicitly indicate a specific geographic location from which 
participants were obtained. 
Other: The sample of participants was obtained from a geographic location other than those 
presented here. 
Not Reported: The geographic location of participants was not reported. 
Author’s Labeling of Participants  
 The diagnosis attributed to an individual participant or group. The author’s/authors’ designation 
of one of the following: 
Autism 
Asperger 
PDD-NOS 
Unclear 
Not Reported 
Other 
Severity of Participants Pre-Test  
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The degree of severity associated with an individual participant’s or group diagnosis. The 
author’s/authors’ designation of one of the following 
Mild 
Mild-Moderate: reference must include both and only these terms 
Moderate 
Moderate-Severe: reference must include both and only these terms 
Severe 
Unclear: A non-specific reference to multi-levels of severity (e.g., all levels of severity were 
represented) 
Mixed: reference to mild, moderate, and severe representation in the same group 
Not Reported: The severity of participants was not reported. 
Education Level of Participants 
The level of education completed by an individual participant or group. The author’s/authors’ 
designation of one of the following: 
Preschool 
K-5 
Middle School (6-8) 
High School (9-12) 
Home School 
Clinic Only 
Unclear: A statement that does not explicitly indicate the formal level of education of a 
participant or group. 
Other: The education level of a participant or group varied from those presented here. 
Not Reported: The education level of participants was not reported. 
Race/Ethnicity  
The ethnic affiliation of an individual participant or group. The author’s/authors’ designation of 
one of the following: 
African American 
American Indian  
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Asian 
Hispanic/Latino 
White/Caucasian 
Unclear: non-specific reference to multiple racial/ethnic group representation (e.g., “…several 
race/ethnic groups were represented in the study.”) 
Mixed: reference must include at least two specific race/ethnic group labels 
Not Reported 
 
Recruitment Pool 
The method for identifying potential participants for assignment into groups. 
Referral - Recommendation as participant(s) based on existing knowledge of participant 
characteristics (e.g., physician referred). 
Criterion - The participants are chosen based on specific characteristics (e.g., score less than a 
specified cutoff score on a test administered before assignment). 
Scores on norm referenced test- The participants are chosen based on scores reported on a norm 
referenced test (e.g., Wechsler Intelligence Scale for Children). 
Existing group - A group already together based on specific characteristics (e.g., outpatients from 
a specialty clinic). 
Volunteer - The participants offer themselves for inclusion in the study (e.g., respond to media 
ad). 
Waiting list – The recruitment pool is comprised of participants who have been on a waiting list 
(e.g., waiting list for an intervention or program). 
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Unclear - A statement that does not explicitly indicate the method of participant recruitment. 
Not Reported - The method of participant recruitment was not reported. 
Other – The method of participant recruitment varied from than those presented here. 
Design Type  
Randomized controlled trial (RCT) - Participants are randomly assigned to either experimental or 
control groups. The researcher manipulates one or more independent variables and measures any 
changes in the dependent variable(s) (Kerlinger & Lee, 2000, p. 491).   
Quasi-experimental - Participants are not randomly assigned to either the experimental or control 
group.  
Subject Assignment 
Individual random -  "Assignment to experimental treatments of members of a universe in a 
ways such that, for any given assignment to a treatment, every member of the universe has an 
equal probability of being chosen for that assignment" (Kerlinger & Lee, 2000, p. 170).  In short, 
participants are randomly assigned to a condition.   
Whole group random - Groups are randomly assigned to an experimental or control group. These 
groups of participants are matched "in terms of overall distribution of the selected variable or 
variables, rather than on an individual-by-individual basis" (Kerlinger & Lee, 2000, p. 491). 
Individual matched-random - Participants are matched on one or more variables and then 
randomly assigned to an experimental or control group. (Kerlinger & Lee, 2000). 
 
 
44 
 
Matched non-random - Participants are matched on one or more variables, but not randomly 
assigned to conditions. 
Non-matched non-random - Participants are not matched on one or more variables and are not 
randomly assigned to condition.   
Unclear - A statement that does not explicitly indicate the method of subject assignment. 
Not reported - Method of subject assignment was not reported. 
Other - Assignment to condition(s) by any method other than those presented here. 
Method of Random Assignment 
Random number generation - Random assignment is utilized using a software program or 
random number table. 
Simple random - Random assignment within groups by participant characteristics (CONSORT 
Statement, 2001). 
Coin flip - Random assignment is completed by the flip of a coin. 
Allocation/Assignment - The generation of an allocation sequence in which the number of 
assignments to intervention groups satisfies a specified allocation ratio (such as 1:1 or 2:1) after 
every "block" of specified size (CONSORT Statement, 2001). 
Unclear - A statement that does not explicitly indicate the method of random assignment. 
Other - Neither random number generated nor coin flip is used to complete the random 
assignment. 
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Not reported – The method of random assignment was not reported. 
Type of Analysis 
Intent to treat - Analysis of trial results which includes the data of all participants whether they 
completed the treatment or not. 
Treat only - Analysis in which only data from participants who completed the trial is used in the 
final results.  
Individual Blinding 
Participants, caregivers, outcome assessors, and analysts are all potential candidates for 
blinding.  However, blinding of certain individuals may not be feasible (i.e., surgeons in surgical 
trials). The author’s/authors’ assigned designation to the following: 
Researcher 
Participants 
Intervener 
Assessor 
No Blinding 
Unclear: A statement that does not explicitly indicate which individuals were blinded during the 
study. 
Not reported: Blinding during the study was not reported. 
 
Group Blinding 
The procedure of preventing those involved in a trial from knowing which comparison group a 
participant belongs. The possibility of bias is reduced when as few people as possible know who 
is receiving the experimental intervention or the control intervention.  
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Open - In an open label experiment, both the researchers and participants are aware of which 
treatment is being administered. 
Single blinding - In a single blind experiment, the individual subjects do not know whether they 
are members of a control group or members of an experimental group.  
Double blinding - In a double-blind experiment, two parties do not know who belongs to the 
control group and the experimental group.  
Triple blinding – In a triple-blind experiment, three parties do not know which participants 
belong to the control group and the experimental group. 
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